Edition:
United States

Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

0.00USD
1:12pm EDT
Change (% chg)

$-0.00 (-16.83%)
Prev Close
$0.01
Open
$0.00
Day's High
$0.00
Day's Low
$0.00
Volume
8,161
Avg. Vol
160,785
52-wk High
$0.20
52-wk Low
$0.00

Summary

Name Age Since Current Position

Barry Kallander

2017 President, Treasurer, Secretary, Director

Stephan Toutain

50 2016 Chief Commercial Officer

Dayton Misfeldt

42 2013 Independent Director

Adam Evertts

2016 IR Contact Officer

Biographies

Name Description

Barry Kallander

Stephan Toutain

Mr. Stephan Toutain is a Chief Commercial Officer of the Company. Mr. Toutain brings more than 25 years of commercial development, market access, and sales and marketing leadership with particular expertise in ultra-orphan drug and orphan oncology markets worldwide. Prior to joining Interleukin, Mr. Toutain spent three years as a successful consultant to the biopharmaceutical industry addressing marketing strategy and access challenges. Previously he headed Global Commercial Development for Sarepta Therapeutics, and served as General Manager for Alexion in Europe. Prior to these roles, Mr. Toutain held various commercial, marketing and product management positions with Alexion Pharmaceuticals, Celgene Corporation, and Johnson & Johnson. Mr. Toutain received a Master of Business Administration from University of North Carolina, and a Master of Engineering in Biotechnology from University of Nancy II in France.

Dayton Misfeldt

Mr. Dayton C. Misfeldt is an Independent Director of the Company., since May 2013. Mr. Misfeldt is a Managing Director at Bay City Capital LLC, a leading, global life sciences investment firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000, Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at Life Science Economics. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego. Mr. Misfeldt currently serves on the Board of Directors of Sunesis Pharmaceuticals, Inc, a publicly traded biopharmaceutical company and several private company boards.

Adam Evertts

Basic Compensation

Name Fiscal Year Total

Barry Kallander

--

Stephan Toutain

--

Dayton Misfeldt

--

Adam Evertts

--
As Of 

Options Compensation